Department of Urology, Meir Hospital, Kfar Saba,
Clin Drug Investig. 2003;23(3):205-15. doi: 10.2165/00044011-200323030-00006.
To present management options for gynaecomastia and mastodynia associated with nonsteroidal antiandrogen therapy, supported by relevant data and case studies.
Gynaecomastia (male breast enlargement) and breast pain/ sensitivity (mastodynia or mastalgia) are pharmacologically expected adverse effects of nonsteroidal antiandrogen therapy for prostate cancer. They are caused by proliferation of glandular tissue in response to an increase in the ratio of estrogen to androgen. Gynaecomastia and mastodynia are benign conditions, and many patients choose to tolerate them as acceptable, usually mild or moderate, adverse effects of therapy. Recent data show that nonsteroidal antiandrogen monotherapy significantly reduces disease progression in localised and locally advanced prostate cancer, a finding that may result in wider and more long-term use of this treatment. Therefore, both clinicians and patients may benefit from increased awareness of the options available for the management of gynaecomastia and mastodynia. Management options, data and case studies: Management options for gynaecomastia and mastodynia are illustrated in a schematic flow diagram. Options identified are: (1) risk reduction using pretreatment breast irradiation; (2) stopping antiandrogen therapy; (3) acceptance of gynaecomastia and/or mastodynia in the context of the significant clinical benefit of antiandrogen treatment; (4) prompt treatment (liposuction/breast tissue excision, hormonal manipulation or pain control with irradiation or analgesics); and (5) later treatment (liposuction/breast tissue excision, hormonal manipulation or pain control with irradiation or analgesics). Where available, relevant data are discussed and the options are illustrated by case studies.
The risk of developing gynaecomastia is lessened by prophylactic breast irradiation. Following the development of gynaecomastia, treatment options include readjustment of the estrogen-to-androgen ratio using antiestrogens, surgery in the form of liposuction or, for more advanced cases, breast tissue excision. Mastodynia may be controlled by post-treatment irradiation or analgesics.
介绍与非甾体类抗雄激素治疗相关的男性乳房发育症和乳房疼痛/敏感性(男性乳房发育症或乳房痛)的管理选择,并提供相关数据和病例研究支持。
男性乳房发育症(男性乳房增大)和乳房疼痛/敏感性(男性乳房发育症或乳房痛)是前列腺癌非甾体类抗雄激素治疗的预期药理学不良反应。它们是由腺体组织增生引起的,这是对雌激素与雄激素比例增加的反应。男性乳房发育症和乳房痛是良性疾病,许多患者选择将其视为可接受的、通常为轻度或中度的治疗不良反应。最近的数据表明,非甾体类抗雄激素单药治疗可显著降低局限性和局部晚期前列腺癌的疾病进展,这一发现可能导致这种治疗的更广泛和更长期使用。因此,临床医生和患者都可能受益于提高对男性乳房发育症和乳房痛管理选择的认识。
管理选项、数据和病例研究:男性乳房发育症和乳房痛的管理选项以示意图流程图的形式呈现。确定的选项包括:(1)使用预处理乳房照射降低风险;(2)停止抗雄激素治疗;(3)在抗雄激素治疗具有显著临床益处的情况下,接受男性乳房发育症和/或乳房痛;(4)及时治疗(吸脂/乳房组织切除术、激素治疗或用放疗或镇痛药控制疼痛);(5)后期治疗(吸脂/乳房组织切除术、激素治疗或用放疗或镇痛药控制疼痛)。在有相关数据的情况下,讨论了相关数据,并通过病例研究说明了这些选择。
预防性乳房照射可降低发生男性乳房发育症的风险。男性乳房发育症发生后,治疗选择包括使用抗雌激素药物调整雌激素与雄激素的比例、吸脂术或更严重病例的乳房组织切除术等手术形式。乳房痛可通过治疗后放疗或镇痛药控制。